Indian Immunologicals Limited (IIL) announced that the company will invest about Rs 700 Crores to set up a new animal vaccine manufacturing facility in Genome Valley, Hyderabad.
The IIL, a subsidiary of the National Dairy Development Board (NDDB), is already one of the world’s largest FMD vaccine manufacturers. It is also the leading vaccine supplier to the Government of India’s National Animal Disease Control Programme (NADCP).
IIL’s Executive Leadership team has briefed Minister K. T. Rama Rao on the company’s plans. The new facility will create total employment for around 750 people.
IIL’s existing facility in Gachibowli already has a capacity of 300 million doses. Its intended new facility, in Genome Valley Phase 3, will add another 300 million doses/annum of FMD vaccine to its capacity.
Minister K. T. Rama Rao said that Hyderabad is already regarded as the Vaccine Capital of the World and IIL’s expansion further advances the contribution in terms of global health, not just for humans but also for animals.
K Anand Kumar, IIL Managing Director, said, “The company is on an aggressive growth path, and this third vaccine facility in Hyderabad will ensure self-sufficiency for our nation in the field of vaccines, thereby saving the exchequer and farmers several thousands of crores of rupees.”
